Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):e7-e11. doi: 10.1016/j.clml.2013.07.101. Epub 2013 Oct 26.

¹ Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany.
² Department of General Pathology, University Hospital of Tuebingen, Tuebingen, Germany.
³ Department of Internal Medicine V and National Center for Tumor Diseases, University Hospital of Heidelberg, Heidelberg, Germany.
⁴ Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany. Electronic address: katja.weisel@med.uni-tuebingen.de.

No abstract available

Keywords: B-cell clonality; EBV; High-dose mephalan; Secondary primary malignancy; Thalidomide.

Publication types